⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25177048 | 1.00 | — | — | |
| SCHEMBL2097443 | 1.00 | — | — | |
| SCHEMBL6210297 | 0.90 | RAB9A (0.38) | — | |
| SCHEMBL2672951 | 0.90 | RAB9A (0.38) | — | |
| SCHEMBL2525150 | 0.90 | RAB9A (0.38) | — | |
| SCHEMBL3089785 | 0.88 | CPT2 (0.40) | — | |
| SCHEMBL3257721 | 0.88 | CPT2 (0.40) | — | |
| SCHEMBL17941198 | 0.88 | CPT2 (0.40) | — | |
| SCHEMBL14676589 | 0.81 | GLI1 (0.32) | — | |
| SCHEMBL14676077 | 0.81 | GLI1 (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111925360-B | 1-heterocyclylisochromanyl compounds and analogs for the treatment of CNS disorders | 赛诺维信制药公司 | 2024-03-22 | — | — | CN | disclosed |
| EP-4006039-B1 | FUSED DIHYDRO-4H-PYRAZOLO[5,1-C][1,4]OXAZINYL COMPOUNDS AND ANALOGS FOR TREATING CNS DISORDERS | SUNOVION PHARMACEUTICALS INC (US) | 2024-01-10 | — | — | EP | disclosed |
| WO-2023199091-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-10-19 | — | — | WO | disclosed |
| CN-111171047-B | Fused dihydro-4H-pyrazolo [5,1-C ] [1,4] oxazinyl compounds for the treatment of CNS disorders | 赛诺维信制药公司 | 2023-06-23 | — | — | CN | disclosed |
| WO-2023081840-A1 | KRAS G12C INHIBITORS | FRONTIER MEDICINES CORPORATION (US) | 2023-05-11 | — | — | WO | disclosed |
| WO-2023064493-A1 | COMPOUNDS AND METHODS FOR TREATING CORONAVIRUSES | Clear Creek Bio, Inc. (US) | 2023-04-20 | — | — | WO | disclosed |
| CN-111925360-A | 1-heterocyclyl isochroman compounds and analogs for the treatment of CNS disorders | 赛诺维信制药公司 | 2020-11-13 | — | — | CN | disclosed |
| CN-107531674-B | 1-heterocyclyl isochroman compounds and analogs for the treatment of CNS disorders | 赛诺维信制药公司 | 2020-07-31 | — | — | CN | disclosed |
| CN-111171047-A | Fused dihydro-4H-pyrazolo [5,1-C ] [1,4] oxazinyl compounds for the treatment of CNS disorders | 赛诺维信制药公司 | 2020-05-19 | — | — | CN | disclosed |
| CN-107567454-B | Fused dihydro-4H-pyrazolo [5,1-C ] [1,4] oxazinyl compounds and analogs thereof for the treatment of CNS disorders | 赛诺维信制药公司 | 2020-02-18 | — | — | CN | disclosed |
| EP-3256466-A1 | 1-HETEROCYCLYL ISOCHROMANYL COMPOUNDS AND ANALOGS FOR TREATING CNS DISORDERS | Sunovion Pharmaceuticals Inc. (US) | 2017-12-20 | — | — | EP | disclosed |
| EP-3256476-A1 | FUSED DIHYDRO-4H-PYRAZOLO[5,1-C][1,4]OXAZINYL COMPOUNDS AND ANALOGS FOR TREATING CNS DISORDERS | Sunovion Pharmaceuticals Inc. (US) | 2017-12-20 | — | — | EP | disclosed |
| WO-2016130796-A1 | 1-HETEROCYCLYL ISOCHROMANYL COMPOUNDS AND ANALOGS FOR TREATING CNS DISORDERS | SUNOVION PHARMACEUTICALS INC. (US) | 2016-08-18 | — | — | WO | disclosed |
| WO-2016130790-A1 | FUSED DIHYDRO-4H-PYRAZOLO[5,1-C][1,4]OXAZINYL COMPOUNDS AND ANALOGS FOR TREATING CNS DISORDERS | SUNOVION PHARMACEUTICALS INC. (US) | 2016-08-18 | — | — | WO | disclosed |
| EP-2320907-A1 | THERAPEUTIC COMPOUNDS | Merck & Co., Inc. (US) | 2011-05-18 | — | — | EP | disclosed |
| EP-2205083-A1 | SUBSTITUTED ARYL SULFONE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | Merck Sharp & Dohme Corp. (US) | 2010-07-14 | — | — | EP | disclosed |
| WO-2010017047-A1 | THERAPEUTIC COMPOUNDS | MERCK & CO., INC. (US) | 2010-02-11 | — | — | WO | disclosed |
| WO-2009045382-A1 | SUBSTITUTED ARYL SULFONE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | MERCK & CO., INC. (US) | 2009-04-09 | — | — | WO | disclosed |